CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes...
Birmingham, Alabama, United States and 43 other locations
the efficacy and safety of icovamenib in participants with Type 2 Diabetes who are not achieving glycemic targets despite antihyperglycemic ...
Phase 2
Birmingham, Alabama, United States and 17 other locations
to standard of care (SOC) on patients with a diagnosis of Type 2 diabetes mellitus (T2DM). Participants will be in this study for 24 to 26 w...
Birmingham, Alabama, United States
This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes...
Phase 2
Birmingham, Alabama, United States and 19 other locations
This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good...
Phase 2
Birmingham, Alabama, United States and 44 other locations
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing ...
Phase 4
Birmingham, Alabama, United States and 89 other locations
implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes...
Birmingham, Alabama, United States and 6 other locations
IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes...
Birmingham, Alabama, United States and 6 other locations
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on:*...
Phase 3
Cullman, Alabama, United States and 173 other locations
This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of t...
Phase 2
Birmingham, Alabama, United States and 4 other locations
Clinical trials
Research sites
Resources
Legal